William Raj Sellers, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 55 | 2023 | 21990 | 1.900 |
Why?
|
| Protein-Arginine N-Methyltransferases | 4 | 2021 | 131 | 1.520 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 4 | 2024 | 81 | 1.480 |
Why?
|
| Phosphoric Monoester Hydrolases | 10 | 2004 | 412 | 1.360 |
Why?
|
| Cell Line, Tumor | 79 | 2024 | 16891 | 1.320 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 4 | 2024 | 319 | 1.210 |
Why?
|
| PTEN Phosphohydrolase | 19 | 2015 | 1114 | 1.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 18 | 2023 | 2859 | 1.010 |
Why?
|
| Antineoplastic Agents | 27 | 2021 | 13603 | 1.000 |
Why?
|
| MAP Kinase Signaling System | 8 | 2021 | 1477 | 0.970 |
Why?
|
| Oncogenes | 8 | 2017 | 1222 | 0.950 |
Why?
|
| Cyclin-Dependent Kinase 4 | 5 | 2021 | 555 | 0.950 |
Why?
|
| Proto-Oncogene Proteins | 22 | 2014 | 4491 | 0.940 |
Why?
|
| Xenograft Model Antitumor Assays | 23 | 2020 | 3575 | 0.930 |
Why?
|
| Biotinylation | 1 | 2024 | 184 | 0.900 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 6 | 2018 | 367 | 0.880 |
Why?
|
| Tumor Suppressor Proteins | 14 | 2004 | 2800 | 0.830 |
Why?
|
| Acidaminococcus | 1 | 2022 | 9 | 0.830 |
Why?
|
| Genes, Tumor Suppressor | 10 | 2010 | 1055 | 0.830 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2021 | 12 | 0.810 |
Why?
|
| Aminopyridines | 7 | 2017 | 564 | 0.800 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2021 | 47 | 0.790 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2021 | 71 | 0.780 |
Why?
|
| Genes, Essential | 2 | 2021 | 184 | 0.780 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 2796 | 0.770 |
Why?
|
| Prostatic Neoplasms | 22 | 2024 | 11075 | 0.750 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2020 | 5254 | 0.720 |
Why?
|
| Cell Proliferation | 23 | 2024 | 10416 | 0.700 |
Why?
|
| Ubiquitination | 1 | 2024 | 1008 | 0.650 |
Why?
|
| Ubiquitin | 1 | 2024 | 837 | 0.640 |
Why?
|
| Pyrimidines | 11 | 2018 | 3005 | 0.610 |
Why?
|
| ras Proteins | 5 | 2018 | 1050 | 0.610 |
Why?
|
| Research Personnel | 1 | 2023 | 582 | 0.610 |
Why?
|
| Allosteric Site | 2 | 2017 | 103 | 0.590 |
Why?
|
| Retinoblastoma Protein | 9 | 2005 | 670 | 0.560 |
Why?
|
| Purines | 2 | 2017 | 605 | 0.560 |
Why?
|
| Mice, Nude | 21 | 2021 | 3602 | 0.550 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2017 | 431 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-akt | 19 | 2013 | 2443 | 0.550 |
Why?
|
| Genetic Techniques | 1 | 2019 | 427 | 0.540 |
Why?
|
| Transcription Factors | 24 | 2018 | 12092 | 0.540 |
Why?
|
| DNA-Binding Proteins | 22 | 2018 | 9574 | 0.530 |
Why?
|
| Cyclin-Dependent Kinase 6 | 4 | 2021 | 345 | 0.530 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2016 | 28 | 0.530 |
Why?
|
| Mutation | 40 | 2023 | 29928 | 0.530 |
Why?
|
| Gene Expression Regulation, Neoplastic | 27 | 2020 | 8505 | 0.530 |
Why?
|
| Protein Kinase Inhibitors | 25 | 2023 | 5639 | 0.520 |
Why?
|
| Signal Transduction | 36 | 2021 | 23342 | 0.520 |
Why?
|
| Cell Lineage | 8 | 2018 | 2533 | 0.520 |
Why?
|
| Cell Cycle | 15 | 2017 | 2930 | 0.510 |
Why?
|
| Gene Amplification | 12 | 2016 | 1086 | 0.510 |
Why?
|
| Imidazoles | 2 | 2019 | 1179 | 0.510 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2018 | 2913 | 0.510 |
Why?
|
| RNA Interference | 5 | 2017 | 2836 | 0.510 |
Why?
|
| Gene Dosage | 12 | 2015 | 1218 | 0.500 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2019 | 1335 | 0.490 |
Why?
|
| Proto-Oncogene Proteins B-raf | 10 | 2023 | 2052 | 0.490 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2024 | 1889 | 0.480 |
Why?
|
| Niacinamide | 1 | 2017 | 413 | 0.480 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 17 | 2015 | 3774 | 0.480 |
Why?
|
| Pyrroles | 2 | 2018 | 1127 | 0.470 |
Why?
|
| RNA, Small Interfering | 10 | 2018 | 3432 | 0.460 |
Why?
|
| Methionine | 1 | 2016 | 569 | 0.440 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 4 | 2020 | 223 | 0.430 |
Why?
|
| High-Throughput Screening Assays | 5 | 2016 | 933 | 0.420 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2013 | 93 | 0.420 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 697 | 0.420 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 5 | 2010 | 259 | 0.410 |
Why?
|
| Neoplasm Transplantation | 11 | 2018 | 2013 | 0.410 |
Why?
|
| Mice | 62 | 2024 | 81107 | 0.400 |
Why?
|
| Protein Kinases | 5 | 2008 | 1610 | 0.400 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2013 | 192 | 0.400 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 685 | 0.400 |
Why?
|
| Genomics | 7 | 2016 | 5788 | 0.380 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 3608 | 0.380 |
Why?
|
| Melanoma | 11 | 2019 | 5690 | 0.370 |
Why?
|
| Humans | 168 | 2024 | 757650 | 0.360 |
Why?
|
| Animals | 82 | 2024 | 167777 | 0.360 |
Why?
|
| Gene Expression Profiling | 22 | 2020 | 9404 | 0.360 |
Why?
|
| Chromosome Aberrations | 5 | 2011 | 1764 | 0.350 |
Why?
|
| Enzyme Activation | 11 | 2021 | 3593 | 0.330 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2023 | 1622 | 0.330 |
Why?
|
| Genome, Human | 7 | 2016 | 4414 | 0.330 |
Why?
|
| Loss of Heterozygosity | 5 | 2008 | 659 | 0.320 |
Why?
|
| Cell Cycle Proteins | 12 | 2005 | 3443 | 0.320 |
Why?
|
| Repressor Proteins | 9 | 2018 | 2976 | 0.310 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 6841 | 0.310 |
Why?
|
| Pyrazoles | 4 | 2017 | 1994 | 0.310 |
Why?
|
| Phosphorylation | 20 | 2021 | 8298 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2019 | 570 | 0.290 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 4 | 2014 | 211 | 0.290 |
Why?
|
| Thiazoles | 2 | 2014 | 1511 | 0.290 |
Why?
|
| DNA, Neoplasm | 11 | 2011 | 1745 | 0.290 |
Why?
|
| HEK293 Cells | 6 | 2024 | 4258 | 0.280 |
Why?
|
| Cell Survival | 12 | 2018 | 5782 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 21 | 2016 | 15773 | 0.270 |
Why?
|
| Protein Binding | 18 | 2021 | 9312 | 0.270 |
Why?
|
| Transcription, Genetic | 13 | 2018 | 7590 | 0.270 |
Why?
|
| Apoptosis | 14 | 2018 | 9469 | 0.270 |
Why?
|
| HCT116 Cells | 5 | 2021 | 402 | 0.270 |
Why?
|
| Morpholines | 5 | 2014 | 580 | 0.260 |
Why?
|
| Carrier Proteins | 9 | 2001 | 4937 | 0.260 |
Why?
|
| Benzamides | 8 | 2019 | 1367 | 0.250 |
Why?
|
| Software | 2 | 2019 | 4416 | 0.250 |
Why?
|
| Allosteric Regulation | 5 | 2020 | 426 | 0.250 |
Why?
|
| Quinazolines | 8 | 2015 | 1371 | 0.250 |
Why?
|
| beta Catenin | 4 | 2023 | 1043 | 0.240 |
Why?
|
| Fibroblast Growth Factors | 3 | 2019 | 867 | 0.240 |
Why?
|
| Phosphoproteins | 6 | 2021 | 2433 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 6 | 2023 | 640 | 0.240 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2015 | 58 | 0.240 |
Why?
|
| Bacillus Phages | 1 | 2004 | 12 | 0.240 |
Why?
|
| Histones | 3 | 2021 | 2577 | 0.220 |
Why?
|
| MAP Kinase Kinase Kinases | 4 | 2018 | 256 | 0.220 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2024 | 304 | 0.220 |
Why?
|
| Epithelial Cells | 7 | 2016 | 3665 | 0.220 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 2211 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 7 | 2015 | 6069 | 0.220 |
Why?
|
| Staurosporine | 1 | 2004 | 242 | 0.220 |
Why?
|
| Cell Line | 17 | 2013 | 15594 | 0.220 |
Why?
|
| Alleles | 7 | 2010 | 6894 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2016 | 2056 | 0.210 |
Why?
|
| Proteins | 4 | 2004 | 6026 | 0.210 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 714 | 0.210 |
Why?
|
| Drug Discovery | 2 | 2021 | 1044 | 0.200 |
Why?
|
| Receptors, Androgen | 4 | 2016 | 1075 | 0.200 |
Why?
|
| Mutation, Missense | 7 | 2011 | 2565 | 0.200 |
Why?
|
| Cell Division | 7 | 2009 | 4459 | 0.200 |
Why?
|
| Protein Structure, Tertiary | 12 | 2016 | 3795 | 0.200 |
Why?
|
| Substrate Specificity | 4 | 2024 | 1791 | 0.200 |
Why?
|
| Kynurenine | 2 | 2019 | 139 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 5272 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 13 | 2020 | 6128 | 0.190 |
Why?
|
| bcl-X Protein | 3 | 2018 | 411 | 0.190 |
Why?
|
| Transcriptional Activation | 5 | 2002 | 1753 | 0.190 |
Why?
|
| Activin Receptors, Type II | 1 | 2001 | 123 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2017 | 2824 | 0.190 |
Why?
|
| Methylation | 2 | 2021 | 1080 | 0.180 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2004 | 489 | 0.180 |
Why?
|
| Spliceosomes | 1 | 2021 | 129 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 726 | 0.180 |
Why?
|
| Genes, Retinoblastoma | 2 | 1997 | 125 | 0.180 |
Why?
|
| Gene Knockout Techniques | 2 | 2021 | 802 | 0.170 |
Why?
|
| Gene Library | 4 | 2017 | 1059 | 0.170 |
Why?
|
| Lung Neoplasms | 13 | 2023 | 13267 | 0.170 |
Why?
|
| Rhabdoid Tumor | 2 | 2013 | 210 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2019 | 17 | 0.170 |
Why?
|
| RNA, Messenger | 6 | 2009 | 12761 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 4 | 2019 | 1609 | 0.170 |
Why?
|
| Rats | 10 | 2020 | 23681 | 0.170 |
Why?
|
| Streptococcus pyogenes | 1 | 2022 | 293 | 0.170 |
Why?
|
| Pyridazines | 1 | 2021 | 200 | 0.170 |
Why?
|
| Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor | 1 | 2019 | 11 | 0.170 |
Why?
|
| Nuclear Proteins | 8 | 2021 | 5786 | 0.170 |
Why?
|
| Phenylurea Compounds | 2 | 2013 | 527 | 0.170 |
Why?
|
| raf Kinases | 2 | 2018 | 118 | 0.160 |
Why?
|
| Protein Conformation | 6 | 2016 | 3967 | 0.160 |
Why?
|
| Asparagine | 1 | 2019 | 119 | 0.160 |
Why?
|
| Piperidines | 3 | 2016 | 1639 | 0.160 |
Why?
|
| Pyrazines | 2 | 2016 | 1198 | 0.160 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 1422 | 0.160 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2016 | 462 | 0.160 |
Why?
|
| Models, Molecular | 11 | 2021 | 5411 | 0.160 |
Why?
|